CATALYST CLINICAL RESEARCH
LIVE

Serial Number

90606290

Owner

Catalyst Clinical Research LLC

Attorney

Philip J. Cardinale

First Use Date

Jun 9, 2013

Filing Date

Mar 26, 2021

Add to watchlist:

No watchlists yet
View on USPTO

CATALYST CLINICAL RESEARCH Trademark

Serial Number: 90606290

CATALYST CLINICAL RESEARCH is a trademark filed by Catalyst Clinical Research LLC on March 26, 2021. The trademark is classified under Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 16 (Paper Goods), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Catalyst Clinical Research LLC (7 trademarks)

Wilmington, NC 28409

Entity Type: 16

Trademark Details

Filing Date

March 26, 2021

Registration Date

Not Registered

First Use Anywhere

June 9, 2013

First Use in Commerce

June 9, 2013

Goods & Services

Regulatory compliance consulting in the fields of pharmaceuticals and medical devices

Non-downloadable online publications in the nature of pamphlets, articles and webinars in the pharmaceutical, medical, health care and life sciences fields

Business consulting and information services in the field of commercializing of pharmaceuticals, medical devices, and biotechnology; project management services for others for business purposes in the field of research and development of pharmaceuticals, medical devices and biotechnology; regulatory submission management, namely, assisting others in preparing and filing applications with the governmental regulatory bodies for approval of new drugs and medical devices; economic forecasting and analysis; market research; medical consulting, namely, consulting services in the field of medical product approval for commercial purposes, providing consulting services in the field of regulatory submission management to medical companies to assist them with applications for medical device approval; clinical trial consulting, monitoring, and oversight, namely, business consulting in the field of clinical trials, namely, management and compilation of computerized databases in the field of clinical trials for business purposes, business consulting and management in the field of clinical trials, namely, management and compilation of computerized databases in the field of clinical trials for business purposes; biostatistical consulting, namely, statistical analysis and reporting services for business purposes; database management in the pharmaceutical fields; providing independent review of clinical trials for business purposes; recruitment and placing patients for participations in clinical trials

Pharmaceutical research and testing services, namely, clinical research conducting clinical trials for others, and regulatory affairs consulting services being business consulting in the field of clinical trials, namely, clinical data and regulatory submission management consulting on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval, all in the field of pharmaceuticals, medical devices, and biotechnology; medical and scientific research, namely, designing, organizing, conducting, monitoring, and managing clinical trials and studies on pharmaceuticals and medical devices for others; scientific research consulting services for others in the field of clinical trials and studies on pharmaceuticals and medical devices; collection, calibration, analysis and reporting of medical and scientific research data in connection with clinical trials and studies on pharmaceuticals and medical devices; development, updating and maintenance of software and databases; providing online computer databases in the fields of research and development of pharmaceuticals, medical devices, and biotechnology; providing a website featuring technology enabling users to remotely track, monitor, analyze, and generate reports with information and statistics from clinical trials and studies on pharmaceuticals and medical devices; Clinical trial consulting, monitoring, and oversight, namely, conducting clinical trials for others, consulting services for others in the field of design, planning, and implementation project management of clinical trials

Printed Matter, namely, brochures, articles, instructional and teaching materials and reports in the fields of research and development of pharmaceutical, medical devices and biotechnology

Downloadable electronic materials in the nature of pamphlets, articles, and e-brochures in the fields of research and development of pharmaceuticals, medical devices, and biotechnology

Filing History

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 17, 2026 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 1, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 31, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sep 30, 2024 RCSC
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 28, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 28, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 28, 2024 REAP
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 29, 2024 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sep 28, 2023 RCSC
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 20, 2023 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 20, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 20, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 20, 2023 REAP
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 31, 2023 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 27, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 27, 2022 GNSL
SUSPENSION LETTER WRITTEN
Sep 27, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 22, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 22, 2022 CRFA
ASSIGNED TO LIE
Aug 22, 2022 ALIE
NOTICE OF REVIVAL - E-MAILED
Jul 28, 2022 NREV
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 27, 2022 TROA
PETITION TO REVIVE-GRANTED
Jul 27, 2022 PETG
TEAS PETITION TO REVIVE RECEIVED
Jul 27, 2022 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
May 27, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 27, 2022 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 5, 2021 GNRN
NON-FINAL ACTION E-MAILED
Nov 5, 2021 GNRT
NON-FINAL ACTION WRITTEN
Nov 5, 2021 CNRT
ASSIGNED TO EXAMINER
Nov 3, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 2, 2021 NWOS
NEW APPLICATION ENTERED
Mar 30, 2021 NWAP